Skip to content

To evaluate the effect of unfractionated heparin on sepsis coagulopathy based on clinical big data

To evaluate the effect of unfractionated heparin on sepsis coagulopathy based on clinical big data

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072521
Enrollment
Unknown
Registered
2023-06-15
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

heparin group:N/A
no-heparin group:N/A

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients admitted to ICU: (1) age =18 years; (2) met the definition of sepsis 3.0 criteria, which was defined as suspected infection combined with an acute increase in sequential organ failure assessment (SOFA) score of =2. (3) The worst SIC-related score within 24 hours after ICU admission was SIC =4.

Exclusion criteria

Exclusion criteria: (1) multiple ICU admissions; (2) age < 18 years, length of ICU stay < 24h; (3) heparin for dialysis or treatment rather than prophylaxis; Low molecular weight heparin or warfarin was given during ICU stay. (4) pregnant women; (5) history of embolism and thrombosis; (6) history of heparin thrombocytopenia; (7) liver failure; (8) chronic kidney disease, stage 5; (9) Malignant tumors. (Disease based ICD9 or ICD10)

Design outcomes

Primary

MeasureTime frame
ICU mortality;

Secondary

MeasureTime frame
mechanical ventilation;AKI;

Countries

China

Contacts

Public Contactzhiye zou

Guohui Nie

zouzhiye@163.com+86 138 2379 8327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026